Loading...
•
Sep 30, 2021
Cocrystal Pharma Q3 2021 Earnings Report
Reported financial results for Q3 2021 and provided an update on development programs and milestones.
Key Takeaways
Cocrystal Pharma reported no revenues for Q3 2021 compared to $489,000 in Q3 2020. R&D expenses were $2.2 million, and G&A expenses were $1.8 million. The net loss for the quarter was $3.9 million, or $0.04 per share.
Focusing on COVID-19 antiviral development programs with the goal of beginning first-in-human clinical studies in 2022.
Expecting comments from the FDA by mid-December on the pre-IND briefing package for the intranasal/pulmonary-delivered SARS-CoV-2 protease inhibitor CDI-45205.
Anticipating selecting a lead candidate from novel SARS-CoV-2 protease inhibitors for oral administration by year-end 2021.
Expecting patient enrollment in the Phase 1 trial for the novel PB2 inhibitor CC-42344 for pandemic and seasonal influenza A to begin in early 2022.
Forward Guidance
The Company expects R&D expenses to increase in the fourth quarter of 2021 due to the advancement of our influenza A program into clinical trials and progress with our pre-clinical COVID-19 program toward clinical development.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...